Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olverembatinib - Ascentage Pharma

Next Previous
X
Search
Drug Profile

Olverembatinib - Ascentage Pharma

Alternative Names: APG 1351; BCR-ABL TKI; D 824; GZD 824; HQP 1351; IBI-348; Orebatinib

Latest Information Update: 02 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Developer Ascentage Pharma; Innovent Biologics
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Piperazines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Cytokine inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Registered Acute myeloid leukaemia
  • Phase III Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Gastrointestinal stromal tumours; Solid tumours
  • Preclinical COVID 2019 infections; Renal cell carcinoma

Most Recent Events

  • 21 Nov 2024 Efficacy and adverse events data from a phase I trial in Chronic myeloid leukaemia and Precursor cell lymphoblastic leukaemia-lymphoma released byAscentage Pharma
  • 06 Nov 2024 Efficacy and adverse events data phase Ib trial in Chronic myeloid leukemia released by Ascentage , ,
  • 13 Sep 2024 Efficacy data from a phase I/II trial in Solid tumors released by Ascentage Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top